🔎 Trials Near Me

Beranda › Penyakit Paru Interstisial › Arizona

Uji klinis Penyakit Paru Interstisial di Arizona

13 studi untuk Penyakit Paru Interstisial mencari peserta di lokasi di Arizona.

Kota di Arizona

Teks studi resmi (Bahasa Inggris)

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • USA027, Phoenix
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07179380

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Arizona Heart Rhythm Center, Phoenix
  • University of Arizona, Tucson
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05798923

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

  • Phoenix, Phoenix
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07473700

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Scottsdale
  • GSK Investigational Site, Scottsdale
  • GSK Investigational Site, Tucson
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05878717

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  • Banner University Medical Center, Phoenix
  • Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06911632

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  • Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix
  • Arizona Pulmonary Specialists, Ltd., Scottsdale
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07285655

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Banner Health - University Medical Center Phoenix, Phoenix
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06388421

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

  • University of Arizona, Tucson
Menerima pesertaStudi observasional
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT01915511

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  • Arizona Pulmonary Specialists, Phoenix
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07175038

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  • Banner University Medical Center Phoenix Lung Institute, Phoenix
  • Norton Thoracic Institute, Phoenix
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05943535

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

  • Arizona Pulmonary Specialists, Phoenix
Menerima pesertaStudi observasional
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT06129240

Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease

  • Mayo Clinic in Arizona, Scottsdale
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT06751069

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

  • HonorHealth Research Institute, Scottsdale
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT05975983

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.